期刊
CURRENT ONCOLOGY REPORTS
卷 24, 期 7, 页码 917-927出版社
SPRINGER
DOI: 10.1007/s11912-022-01247-7
关键词
Hepatocellular carcinoma; Multikinase inhibitor; Immune checkpoint inhibitor
类别
The combination therapy with ICIs in the treatment of advanced HCC has shown advantages and is currently being evaluated in large randomized Phase 3 trials as first-line treatment. Other stages of therapy and exploration of predictive biomarkers are also ongoing, which are expected to further improve patient outcomes in the future.
Purpose of review The systemic treatment of advanced hepatocellular carcinoma (HCC) has significantly evolved. Immune checkpoint inhibitors (ICIs) have demonstrated clinical efficacy and more favorable toxicity profiles compared to multikinase inhibitors. Combination therapy with ICIs may provide greater anti-tumor activity compared to ICI monotherapy. This review will discuss the current treatment landscape of advanced HCC, with a focus on recently completed and ongoing trials of ICI combinations, as well as future directions. Recent findings Atezolizumab/bevacizumab has been approved as first-line therapy in patients with advanced HCC based on its superiority over sorafenib in the pivotal IMbrave150 trial. Similarly, durvalumab/tremelimumab demonstrated an improvement in overall survival compared to sorafenib in the HIMALAYA trial. Other combinations of ICIs with targeted agents and dual immune checkpoint blockade are currently being investigated in large randomized Phase 3 trials for the first-line treatment of HCC. Summary Results of several ICI combination trials have been reported or are anticipated in the next few years and may potentially expand the therapy options in this patient population. Further areas of exploration include the use of ICIs in earlier stages of disease, other immunotherapy approaches such as adoptive T cell therapy, and the identification of predictive biomarkers. These ongoing efforts will likely further improve patient outcomes in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据